Truist Financial Corp Provention Bio, Inc. Transaction History

Truist Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$3.4 - $7.88 $510,000 - $1.18 Million	-150,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $27,950 - $36,950	-5,000 Reduced 3.23%	150,000 $843,000
Q3 2021 Nov 05, 2021	SELL	$5.66 - $8.33 $367 - $541	-65 Reduced 0.04%	155,000 $992,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $241,996 - $398,157	36,065 Added 30.31%	155,065 $1.31 Million
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $212,519 - $408,450	-21,000 Reduced 15.0%	119,000 $1.25 Million
Q4 2020 Nov 19, 2021	SELL	$11.79 - $18.94 $40,663 - $65,324	-3,449 Reduced 2.4%	140,000 $2.37 Million
Q4 2020 Feb 18, 2021	BUY	$11.79 - $18.94 $229,303 - $368,364	19,449 Added 15.68%	143,449 $2.43 Million
Q3 2020 Nov 13, 2020	BUY	$10.34 - $15.2 $103,400 - $152,000	10,000 Added 8.77%	124,000 $1.59 Million
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $234,300 - $510,000	30,000 Added 35.71%	114,000 $1.61 Million
Q1 2020 May 15, 2020	BUY	$5.42 - $17.75 $173,440 - $568,000	32,000 Added 61.54%	84,000 $773,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $303,680 - $774,800	52,000 New	52,000 $775,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.